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Abstract: In chronic obstructive pulmonary disease (COPD)  the inflammation occurring in the 
airways and in other lung tissues is complex and is orchestrated by various mediators including the 
isoenzyme 4 of the phosphodiesterases family (PDE4), which contributes to bronchoconstriction 
and inflammation. Various PDE4 inhibitors have been evaluated as potential therapies in asthma 
or COPD but among these only roflumilast have been authorized in Europe to be used in patients 
with severe COPD as an add-on to the bronchodilator therapy. This review discusses the existing 
preclinical and clinical data supporting the use of roflumilast for this therapeutic indication and 
tackles some of the pending issues related to PDE4 in general and to roflumilast in particular.
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Introduction
COPD is an inflammatory disease of the airways related mainly to smoking and char-
acterized by airflow limitation, which manifests clinically with dsypnea, cough,   
and sputum production, symptoms that aggravate disease severity and disease 
exacerbation.
Chronic airways inflammation leads to their progressive obstruction, lung paren-
chyma damage, and mucus hypersecretion. Subsequently these result in abnormalities 
in gas exchange at the pulmonary level and respiratory failure.
Currently COPD is classified in 4 stages of severity depending on the degree of 
airways obstruction measured by FEV1 and with FEV1/FVC% ratio (Table 1).
In COPD the therapeutic approach is aimed at treating disease exacerbation when 
this occurs and at slowing disease progression in the stable state. In the latter, smoking 
cessation is the main therapeutic intervention able to slow significantly disease 
progression in smoking-related COPD. Apart from smoking cessation, other 
therapeutic approaches such as bronchodilator and anti-inflammatory therapies are 
applied differently according to the disease severity in order to reduce airway 
obstruction, the underlying inflammation, the progression of respiratory symptoms, 
and the risk of exacerbations (Table 1).1
Several classes of bronchodilators are used in the treatment of stable COPD such 
as inhaled β2 agonists (short- and long-acting), inhaled anticholinergics (short- or 
long-acting), and methylxantines. These therapies were found to improve lung 
function especially on a short-term basis and were also reported to significantly 
ameliorate   health-related quality of life, by reducing dyspnea levels and increasing 
exercise capacity.1International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Inhaled corticosteroids still represent the main anti- 
inflammatory treatment in COPD despite more modest clinical 
efficacy than in asthma, due to a less “corticosteroid-sensitive” 
pattern of inflammation. Again unlike asthma, in COPD this 
type of medication is given only in more advanced stages 
(III and IV), usually combined with long-acting β2 agonists in 
order to reduce the number of exacerbations.1–3
COPD pathogenesis
The main inflammatory cells involved in COPD pathogenesis 
are CD8+ (cytotoxic) T-lymphocytes, macrophages, and 
neutrophils which interact to develop and maintain a chronic 
inflammation in the airways and other lung tissues.1,4
CD8+ (cytotoxic) T-lymphocytes have been found in 
high numbers in biopsies of smoking-induced COPD 
patients, and it is thought that they interact with activated 
CD4+ T-lymphocytes in order to produce various proinflam-
matory mediators such as interleukin (IL)-2, interferon-γ 
(IFN-γ), tumor necrosis factor-α (TNF-α), perforines, or 
granzymes which are directly involved in alveolar tissue 
destruction.4–6 Macrophages were also detected in the airways 
of patients with COPD and they play an potentiating role for 
the underlying neutrophilic inflammation, especially by 
producing mediators such as TNF-α or leukotriene B4.1,4,7
In COPD neutrophils are responsible mainly for synthesis 
and release of proteinases and reactive oxygen species, which 
destroy  normal  lung  tissue  and  stimulate  mucus 
hypersecretion.8
Targeting PDE4 pathway in COPD
Phosphodiesterases (PDEs) are cAMP-, or cGMP-specific 
enzymes which have a ubiquitous distribution in the human 
organism. To date 11 isoenzyme groups with various 
  isoforms have been identified.9 Of particular interest for this 
review is the PDE4 isoenzyme, which hydrolyzes cAMP 
and is expressed in lung structural cells such as smooth 
muscle cells, airway epithelium, and inflammatory cells such 
as neutrophils, lymphocytes, or macrophages.10
PDE4 has emerged over the past 2 decades as a promising 
therapeutic target in airway inflammatory diseases such as 
asthma or COPD. The initial focus was on asthma based on 
the assumption that PDE4 inhibition would result in bron-
chodilation and reduction of underlying eosinophilic 
  inflammation. However, subsequent results of preclinical 
testing showing potent anti-inflammatory effects on patterns 
of inflammation rather similar to those of COPD, as well 
as a modest bronchodilatory effect, that drew attention to 
PDE4 inhibition for COPD.
Several PDE4 inhibitors were developed, including ini-
tially rolipram, cilomilast, and roflumilast. Among these, 
roflumilast was the first to be developed and approved for 
market (in Europe) as a COPD therapy.
Nonspecific inhibition of PDE4 in COPD: 
the role of methylxantines
Methylxantines, although no longer commonly used due to 
their limited efficacy, are rather known for their bronchodila-
tor activities. However they also have been demonstrated to 
exert a range of anti-inflammatory activities on various 
inflammatory pathways such as arachidonic acid metabolites, 
TNF-α, nuclear factor-κB, phosphoinositide 3-kinase, 
or PDEs.11,12
Theophylline is a methylxanthine most known and used 
in COPD treatment as a second-line bronchodilator, although 
Table 1 Stable COPD classification and current pharmacologic therapies according to the disease severity1
COPD stage I  
FEV1%pred . 80%  
FEV1/FVC , 70%
COPD stage II  
FEV1%pred 50%–80%  
FEV1/FVC , 70%
COPD stage III  
FEV1%pred , 50%  
FEV1/FVC , 70%
COPD stage IV  
FEV1%pred , 30% or 
FEV%pred 30%–50% and  
chronic respiratory 
failure
Inhaled medications 
Short-acting  
bronchodilators 
β2 agonists 
anticholinergics 
→rescue use←
Long-acting  
bronchodilators 
β2 agonists 
anticholinergics
→regular therapy←
Inhaled corticosteroids →regular therapy←
Notes: www.goldcopd.com The GOLD workshop Report (Updated 2008): Global strategy for the diagnosis, management and prevention of chronic 
obstructive pulmonary disease.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
149
Roflumilast for COPD therapy
its efficacy is counterbalanced by its narrow therapeutic range 
of  plasma  concentrations  (10–20  mg/L),   
poor tolerability and safety profile.13 The bronchodilator 
activity of theophylline is believed to be due to its nonselective 
inhibition of PDEs in airway smooth muscle cells.12,14,15
In COPD patients short-term treatment with high doses 
of theophylline given alone or as an add-on therapy to other 
bronchodilators and corticosteroids improved lung function 
and respiratory symptoms such as dyspnea.16,17
In terms of anti-inflammatory activities, theophylline 
given to COPD patients dosed to achieve plasma levels lower 
than or within the range 9 to 11 mg/L to produce broncho-
dilation, reduced neutrophil count, IL-8, myeloperoxidase, 
and neutrophil elastase levels in sputum.18–23
Theophylline was demonstrated to be a weak and non-
selective inhibitor of several PDE isoforms in the airways, 
such as PDE3, -4, and -5, which was hypothesized to cause 
the bronchodilation.14 Its nonselectivity might also explain 
the occurrence of side effects such as nausea or headaches 
which are caused by PDE4 inhibition.24
Selective PDe4 inhibition in preclinical  
studies in asthma and COPD: focus  
on roflumilast
Roflumilast (3-cyclo-propylmethoxy-4-difluoromethoxy-N-
[3,5-di-chloropyrid-4-yl]-benza mide) was identified as a 
potent and selective PDE4 inhibitor and was demonstrated 
to increase the levels of intracellular cAMP to a lesser extent 
in the bronchial smooth muscle cells and to a greater extent 
in inflammatory cells such as neutrophils, monocytes, den-
dritic cells, or CD4+ T cells, and in the epithelial cells of the 
airways and pulmonary vessels: the most striking effects were 
reported in vitro with both roflumilast and its metabolite 
roflumilast N-oxide on leukotriene b4, reactive oxygen 
  species, TNF-α, IFN-γ, or granzyme B.15,25,26
Some of the studies evaluated the effects of roflumilast 
in asthma animal models whereas most evaluated this 
PDE4 inhibitor in animal models of COPD.
Roflumilast was assessed in an ovalbumin (OVA)-sensitized 
and challenged Brown Norway rat model, and its anti- 
inflammatory activities were compared with those of other 
PDE4 inhibitors, rolipram, piclamilast, and cilomilast. 
  Animals received these treatments before OVA challenge and 
airway hyper-responsiveness (AHR), and brochoalveolar 
lavage (BAL), neutrophil counts and TNF-α levels were 
quantified after allergen challenge. Roflumilast was found 
to be the most potent inhibitor of AHR and of neutrophil 
influx in the lungs among the compounds tested, and also 
demonstrated the greatest suppressing effects on TNF-α. 
However roflumilast had no effect on serotonin-induced 
bronchoconstriction, suggesting that this compound had 
anti-inflammatory rather than bronchodilating effects.27
cAMP has an inhibitory effect on cell proliferation and 
therefore it has been postulated that PDE4 inhibitors might 
exert an antiremodeling effect on the airways.10
In OVA-sensitized and challenged guinea pigs, roflumi-
last given again before OVA-challenge reduced AHR and the 
release of cysteinyl leukotrienes.28
The anti-inflammatory effects of roflumilast might also 
result in a reduction of airway remodeling, as demonstrated 
in a study performed in a mice asthma model with chronic 
allergen exposure in which roflumilast, given after the allergic 
inflammation developed, demonstrated antifibrotic effects 
comparable with those of dexamethasone.29 Roflumilast 
N-oxide, the active metabolite of roflumilast, inhibited 
TNF-α-induced ICAM-1 and eotaxin release in human fetal 
lung fibroblast cell line bFGF, and TGFβ1 profibrotic 
activities.30
In an animal model of tobacco-induced COPD, roflumi-
last given after smoking-related lung inflammation had 
developed, reduced the recruitment of neutrophils from the 
lung microvasculature and the BAL protein content.31 
When given in a rat model of exacerbated COPD,   roflumilast 
reduced BAL neutrophil count and mucus   hypersecretion.32 
The anti-inflammatory effects of roflumilast in the initial 
experiments were found to be quite   heterogeneous in terms 
of amplitude and the type of inflammatory cell targeted by 
this compound, probably a result of the limited exposure to 
tobacco smoke.33 A subsequent study demonstrated that the 
anti-inflammatory effects of roflumilast differed according 
to inflammation pattern: for example in a model of neutro-
philic airway inflammation induced by “acute” smoking 
exposure, roflumilast given in 2 different dosages reduced 
the number of these cells, whereas in a chronic smoke expo-
sure model the anti-inflammatory effects were reported only 
with the higher dose and consisted of a reduction in mac-
rophage inflammation and the size of emphysema lesions, 
and in preservation of lung desmosine content, but had no 
effect on goblet cell   metaplasia.34 Furthermore in a chronic 
exposure model a lower dose of roflumilast was effective 
against the recruitment of dendritic cells and T-lymphocytes, 
whereas the higher dose had a “universal” anti-inflammatory 
effect on all   inflammatory cell types.35
In EGF-stimulated human airway epithelial cells (A549) 
line and in human isolated bronchial tissue, roflumilast 
reduced EGF-related increase in MUC5AC gene and International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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  protein expression, its inhibitory effect being more potent 
than that of other PDE4 inhibitors such as rolipram or 
cilomilast.36
Roflumilast: clinical data in COPD
Roflumilast (Daxas®, Nycomed, Zurich, Switzerland) has 
recently been approved in Europe as an add on to broncho-
dilator treatment for the treatment of severe COPD (FEV1% 
predicted , 50%) associated with chronic bronchitis in adult 
patients with a history of frequent exacerbations.
So far both short- and long-term romflumilast has been 
evaluated for effects on lung function, exacerbation rate, and 
quality of life. The most relevant data supporting the efficacy 
and safety of roflumilast come from several studies, which 
also enabled the COPD subset to benefit most from such a 
therapy to be identified (Table 2).
In an earlier clinical study in which 38 patients with 
COPD received 500 µg roflumilast or placebo once daily for 
4 weeks, roflumilast significantly reduced sputum neutrophils 
and eosinophil counts compared with placebo by 35.5% 
(95% CI 15.6%–50.7%; P = 0.002) and 50.0% (95% CI 26.8%–
65.8%; P , 0.001), respectively.   Roflumilast also signifi-
cantly reduced the levels of soluble IL-8, neutrophil elastase, 
eosinophil cationic protein, and alpha(2)-macroglobulin in 
sputum and the release of TNF-α from blood cells, and also 
improved lung function   (postbronchodilator FEV1).37
A subsequent phase III, multicenter, double-blind, random-
ized, placebo-controlled study (The RECORD, M 2-107) was 
performed in 1411 patients who received either roflumilast 
250 µg (n = 576), roflumilast 500 µg (n = 555), or placebo 
(n = 280) given orally once daily for 24 weeks. Primary out-
comes were represented by postbronchodilator FEV1 and 
health-related quality of life whereas secondary outcomes 
included other lung function parameters and COPD exacerba-
tions. Roflumilast significantly improved postbronchodilator 
FEV1 (by 74 mL at the lower dose and by 97 mL at the higher 
dose compared with placebo; P , 0.0001). Roflumilast at the 
higher dose had the most significant effect on the mean exac-
erbation rate, the higher dose-group demonstrating the lowest 
mean number of COPD exacerbations (1.13 excacerbations 
per patient in placebo group, versus 1.03 in roflumilast 250 
µg, versus 0.75 in roflumilast 500 µg). This effect was mainly 
due to the reduction in the number of mild exacerbations (42% 
reduction in number of mild exacerbations with roflumilast 
500 µg compared with   placebo). The most common adverse 
events were moderate and severe COPD exacerbations and 
nasopharyngitis.   Diarrhea was the most common medication-
related adverse event followed by nausea and headache.38
Table 2 Long-term studies involving roflumilast
Study Duration  Treatment Baseline mean  
postbronchodilator  
FEV1%pred
Sample Primary endpoint
The ReCORD  
(M2-107)
24 weeks Roflumilast 250 µg,  
roflumilast 500 µg,  
placebo
54 N = 1411 Change from baseline in 
postbronchodilator Fev1 
Change from baseline in HRQoL 
scores (SGRQ)
The OPUS  
(M-111) and The  
RATIO (M-112)
52 weeks Roflumilast 500 µg  
once daily or placebo
37 N = 2686 (post-hoc  
analysis sample)
Change from baseline in  
postbronchodilator Fev1 and  
exacerbation rate
The eOS  
(M 2-127)
24 weeks Roflumilast 500 µg +  
salmeterol once daily or  
placebo + salmeterol
55% N = 933 Change from baseline in  
prebronchodilator Fev1
The HeLIOS  
(M 2-128)
24 weeks Roflumilast 500 µg once  
daily + tiotropium or  
placebo + tiotropium
55% N = 743 Change from baseline in  
prebronchodilator Fev1
The AURA  
(M-124)
52 weeks Roflumilast 250 µg,  
roflumilast 500 µg,  
placebo
,50%  N = 1523 Change in prebronchodilator Fev1   
from baseline 
The rate of moderate and severe 
exacerbations
The HeRMeS  
(M-125)
52 weeks Roflumilast 250 µg,  
roflumilast 500 µg,  
placebo
,50% N = 1568 Change in prebronchodilator Fev1   
from baseline 
The rate of moderate and severe 
exacerbations
Abbreviations: HRQoL, health-related quality of life; SGRQ, St. George’s Respiratory Questionnaire.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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OPUS and RATIO studies
The OPUS (M2-111) and the RATIO (M2-112) were 
replicated, randomized, double-blind, placebo-controlled 
studies evaluating the effects of oral roflumilast 500 µg 
versus placebo once daily for 52 weeks in COPD patients 
with moderate to severe disease.
The RATIO study enrolled a total of 1513 patients with 
a mean postbronchodilator FEV1 of 41%. The primary effi-
cacy endopoints were postbronchodilator FEV1 and exacer-
bation rate, whereas health-related quality of life was the 
secondary endpoint.39,40 Roflumilast significantly increased 
FEV1 (39 mL, P = 0.001) but had no significant therapeutic 
effect on the other 2 endpoints; in the subset of the patients 
with GOLD IV stage of the disease, roflumilast improved 
lung function and significantly reduced mean exacerbation 
rate (1.01 versus 1.59 exacerbations per patient per year, 
P = 0.024).40 Adverse events related to roflumilast treatment 
were diarrhea, nausea, and headache, which resolved without 
intervention as the treatment continued.
In a post-hoc pooled analysis including a total of 
2686 patients in both the OPUS and the RATIO studies hav-
ing a mean postbronchodilator FEV1 of 37%, “roflumilast 
  responders” had a clinical phenotype of chronic bronchitis, 
were frequent exacerbators, and had a postbronchodilator 
FEV1 , 50%. In this subset of patients roflumilast reduced 
the exacerbation rate by about 26% (P = 0.001) compared 
with placebo, whereas in the subset with emphysema its 
effect was comparable to that of placebo. A significant 
therapeutic benefit was also seen in patients also receiving 
concomitant inhaled corticosteroids in whom roflumilast 
was found to reduce the exacerbation rate by 18.8% 
(P = 0.014).39,41,42
eOS and HeLIOS studies
The EOS and HELIOS studies compared the efficacy and 
safety of roflumilast versus placebo in patients with COPD 
receiving long-acting bronchodilators such as salmeterol 
(EOS, M2-127) or tiotropium (HELIOS, M2-128). General 
inclusion criteria were represented by patients with stable 
COPD, current or ex-smokers, with a smoking history of at 
least 10 pack-years, and postbronchodilator FEV1% predicted 
40% to 70%. Specific inclusion criteria were presence of 
respiratory symptoms of chronic bronchitis, chronic cough, 
and sputum production and by the frequent use of β2 agonists 
while on tiotropium therapy of at least 3 months’ 
duration.43
After an initial 4-week run in period during which 
patients were given a placebo tablet once daily, patients with 
no moderate to severe COPD exacerbations during this 
period were randomized to either roflumilast 500 µg once 
daily in the morning or placebo for 24 weeks.43
The primary endpoint in both studies was change in 
prebronchodilator FEV1, and the secondary endpoints 
included postbronchodilator FEV1, FVC, and Transition 
Dyspnea Index score, the Shortness of Breath Questionnaire, 
exacerbation rate, and the use of rescue medications. Safety 
endpoints were also included.
The EOS study enrolled 933 patients, 466 in the treatment 
and 467 in the placebo arms, respectively, whereas the 
HELIOS study enrolled 743 patients, 371 in the treatment 
arm and 372 in the placebo arm. The populations in both 
studies were uniform in terms of age, male predominance, 
the higher prevalence of ex-smokers, and adherence rate. 
All patients in the HELIOS study presented with chronic 
cough and sputum. The 2 populations differed in terms of 
use of rescue medication, which was higher at baseline in 
the HELIOS study.43
In both trials probability of study discontinuation was 
higher in patients receiving roflumilast and significantly 
higher in patients receiving salmeterol. Roflumilast 
improved lung function overall by increasing prebroncho-
dilator and postbronchodilator FEV1, and prebronchodilator 
and postbronchodilator FVC, and FEV1 improvements were 
shown in all disease severity subsets, irrespective of the 
smoking status.
In the EOS study, roflumilast significantly prolonged the 
median time to first moderate or severe exacerbation and 
significantly reduced the proportion of patients experiencing 
an exacerbation throughout the study period in general, 
and the proportion of patients with moderate or severe 
  exacerbation in particular.
In the HELIOS study roflumilast significantly reduced 
the overall proportion of patients with an exacerbation and 
significantly prolonged median time to first exacerbation; it 
also reduced dyspnea severity, and improved health-related 
quality of life and significantly reduced the use of rescue 
medication.43
AURA and HeRMeS studies
The AURA (M-124) and the HERMES (M-125) studies were 
placebo-controlled, double-blind, multicenter studies in 
patients with severe and very severe COPD (postbronchodi-
lator FEV1 , 50%), cough, and sputum production and at 
least 1 exacerbation requiring systemic corticosteroids in the 
previous year. After a 4-week run in period, during which 
patients were given a placebo tablet once a day, their use of International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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short-acting bronchodilators, and cough and sputum produc-
tion were recorded, they were randomized to receive either 
roflumilast 500 µg or placebo once daily for the next 
52 weeks, and were allowed to take short- and long-acting 
β2 agonists but not long-acting anticholinergics or inhaled 
corticosteroids. The primary endpoints were the change in 
prebronchodilator FEV1 from baseline and the rate of 
moderate and severe exacerbations. The secondary endpoints 
included postbronchodilator FEV1 change from baseline, 
time to mortality, systemic inflammation (assessed with 
C-reactive protein), health utility scores, dyspnea change 
over study period, and safety.44–46
The AURA study included 1523 patients, 765 in the 
roflumilast arm and 758 in the placebo arm, whereas the 
HERMES study included 1568 patients, 772 in the roflumi-
last arm and 796 in the placebo arm. In both studies a total 
of 1537 patients received roflumilast and 1554 received 
placebo (pooled analysis). Roflumilast improved the primary 
endpoints in each study. A pooled analysis of both studies 
showed: prebronchodilator FEV1 39 mL (P = 0.0003) in 
AURA study, 58 mL (P , 0.0001) in HERMES study, and 
48 mL (P , 0.0001) in both studies; moderate or severe 
exacerbation mean rate 1.08 versus 1.27 exacerbations per 
patient per year (P = 0.0278) in the AURA study, 1.21 versus 
1.49 exacerbations per patient per year (P = 0.0035) in the 
HERMES study and 1.14 versus 1.37 exacerbations per 
patient per year (P = 0.0003) in both studies.44 The effect on 
exacerbations was manifested mainly in moderate exacerba-
tions, as the therapeutic effect on severe exacerbations was 
comparable with that in placebo. Roflumilast also signifi-
cantly improved postbronchodilator FEV1 and reduced 
dyspnea severity but had no effect on systemic inflammation, 
time to mortality, and health utility scores.44
In the pooled analysis adverse events were reported in 
1040 (67%) of patients receiving roflumilast and 963 (62%) 
patients receiving placebo; the most frequent adverse events 
leading to roflumilast discontinuation were nausea, diarrhea 
and headache.44
PDe4 inhibitors use in COPD:  
limitations and side effects
The initial gastrointestinal side-effects such as nausea or 
diarrhea reported with the nonselective PDE inhibitor theo-
phylline drew the attention to the potential physiological 
involvement of these enzymes in prevention of such effects.
Because PDE4s selective inhibition was found to be 
associated with similar effects, further research was done to 
identify the pathogenic role of the inhibition of these 
enzymes in emetogenesis. It was discovered that the emesis 
mechanism is neuronal and related to the increase of cAMP 
by theophylline or by selective PDE4 inhibitors in area 
postrema.47
Among the 4 PDE4 isoforms identified to date, 
A, B, C, and D, PDE4D inhibition was identified as having the 
highest emetogenic potential, as PDE4D gene deletion was 
associated with a significant reduction in the emesis.48–50
In clinical studies evaluating roflumilast, the incidence 
of adverse events was about 16% with roflumilast compared 
with 5% with placebo. The most commonly reported adverse 
events were: diarrhea (5.9%), weight loss (3.4%), nausea 
(2.9%), abdominal pain (1.9%), and headache (1.7%).26 
These adverse reactions occurred mainly during the first 
weeks of therapy and disappeared subsequently with treat-
ment continuation. Roflumilast therapy was associated with 
an increased risk of psychiatric disorders such as insomnia, 
anxiety, nervousness, and depression.26 Suicidal ideation and 
behavior were also rarely detected in clinical trials, and based 
on these findings roflumilast is not recommended in patients 
with a history of depression associated with suicidal ideation 
or behavior.26
Other concerns related to PDE4 inhibition were, fortu-
nately, raised based only on results of preclinical   experiments: 
there have been reports of mesenteric vasculitis, heart failure, 
or arrhythmia.9,51
Another important issue is the proinflammatory effects 
of roflumilast detected at very high doses (100 mg/kg), again 
in preclinical studies. It has been suggested that PDE4 inhibi-
tors may have proinflammatory properties.52 However at the 
currently approved roflumilast dosage, the occurrence of 
such effects is almost impossible.
PDE4 inhibitors: perspective issues
Based on the existing large body of clinical data, the efficacy 
of roflumilast is well established and the place of this type 
of compound in COPD therapy is quite well delineated. 
However some other issues remain to be clarified, including 
the safety profile and the systemic anti-inflammatory effects 
of roflumilast in COPD.
The major safety issue is the emetogenic potential of 
roflumilast, given its inhibitory effects on the PDE4D 
isoform. However this effect, even at the therapeutic dose 
currently approved, has rarely been reported, and further 
research is needed in order to clarify the risk factors for 
this event.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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COPD is currently recognized as a disease of the airways 
in which local inflammation may be accompanied by systemic 
inflammation. Given that roflumilast is an oral PDE4 inhibitor 
and exerts systemic effects, it can presumably also reduce 
systemic inflammation. Such effects have not yet been 
  documented and their demonstration would provide additional 
data in support of the use of roflumilast in COPD.
Other PDE4 inhibitors are currently under development 
in an attempt to overcome side-effects such as nausea and 
vomiting reported with the PDE4 inhibitors. Among the 4 
PDE4 isoforms, PDE4B exerted the most potent proinflam-
matory effects: in mice lipopolysaccharide challenge was 
associated with an increase in PDE4B expression and activity 
and with an increase in TNF-α in the peripheral leucocytes 
and peritoneal macrophages, responses that were absent or 
blunted in PDE4B-deficient mice.53,54 Furthermore in mice 
asthma, PDE4B was demonstrated to play a crucial role in 
the development of allergen-induced Th2-driven airway 
inflammation.55
Such results have supported the development of selective 
PDE4B inhibitors, and recently 4-(substituted amino)-1  -
alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides were reported 
recently to be potent and selective PDE4B inhibitors which 
inhibited lipopolysaccharide-induced TNF-α production 
from isolated human peripheral blood mononuclear cells.56
Other PDE4 inhibitors are currently in development 
either as oral or as inhalation formulations. Roflumilast has 
been evaluated as an inhaled formulation in a rat model of 
OVA-induced asthma and its anti-inflammatory and bron-
chodilator effects have been demonstrated.57 However to date 
inhaled roflumilast has been assessed in the COP setting. 
Another inhaled PDE4 inhibitor, 1-[[5-(1(S)-aminoethly)-2-
[8-methoxy-2-(triflurormethyl)-5-quinolinyl]-4-oxazolyl]
carbonyl]-4(R)-[(cyclopropylcarbonyl)amino]-L-proline, 
ethyl ester xinafoate salt, was also recently found in preclini-
cal studies to inhibit the human PDE4 and to exert anti- 
inflammatory and bronchodilator effects which were 
synergistic with corticosteroids or β2 agonists.58
Conclusion
Roflumilast is the first selective PDE4 inhibitor approved 
in Europe as an add-on anti-inflammatory therapy in 
patients with symptomatic severe COPD with frequent 
exacerbations. This indication is supported mainly by the 
substantial clinical data demonstrating its ability to reduce 
exacerbation rate and to improve lung function in this 
disease subset.
However two main issues are still pending: long-term 
safety and systemic anti-inflammatory effects. If the safety 
profile associated with long-term use proves to be similar to 
that shown in the clinical studies performed during its clinical 
development, the “clinical position” of roflumilast as a safe 
and effective medication for COPD therapy would be 
strengthened. Furthermore such data would help to detect 
potential risk factors for emetogenesis, which is the main 
side effect associated with roflumilast use.
Documentation of the systemic anti-inflammatory effects 
would further support the efficacy of roflumilast for COPD.
To conclude, roflumilast is the newest anti-inflammatory 
therapy which can be used in COPD and can significantly 
affect disease progression.
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